Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



上海醫藥集團股份有限公司

Shanghai Pharmaceuticals Holding Co., Ltd.*

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02607)

SUPPLEMENTAL ANNOUNCEMENT DEEDMED DISPOSAL OF SPHC

We refer to the announcement of Shanghai Pharmaceuticals Holding Co., Ltd. (the "Company") dated 10 February 2021 in relation to the deemed disposal of SPHC (the "Announcement"). Unless otherwise defined, terms used herein shall have the same meanings as those defined in the Announcement.

The Company hereby provides further details in respect of SPHC and Shanghai Healthcare Capital Partnership (Limited Partnership) (上海生物醫藥產業股權投資基金合夥企業(有限合夥)) ("Shanghai Healthcare Capital").

SPHC

SPHC is a joint stock company incorporated under the PRC laws and is mainly engaged in pre-market clinical medicine supply chain, marketed Chinese medicine circulation, patient services and innovative payment, and post-market data analysis. Details of the shareholding structure of SPHC immediately before and after the Capital Increase are set out below.

| Shareholders | Shareholding percentage immediately before the Capital Increase | Shareholding percentage immediately after the Capital Increase |
|--|---|--|
| Company | 5.250% | 3.462% |
| SPH Holding | 67.498% | 44.512% |
| Jingdong Century Trade Co., Ltd. | 11.362% | 7.493% |
| (北京京東世紀貿易有限公司) | | |
| Zhuhai Aiqi Yongxing Management Consulting | 4.547% | 2.998% |
| Enterprise (Limited Partnership) | | |
| (珠海愛奇永興管理諮詢企業(有限合夥)) | | |

| Shenzhen Dongxing Jiaoying International Equity | 4.547% | 2.998% |
|---|--------|---------|
| Investment Partnership (Limited Partnership) | | |
| (深圳東興交盈國際股權投資合夥企業(有限合夥)) | | |
| Shanghai Shengtai Investment Management Co., Ltd. | 4.547% | 2.998% |
| (上海盛太投資管理有限公司) | | |
| Hangzhou Jingxin Investment Partnership (Limited | 1.380% | 0.910% |
| Partnership) | | |
| (杭州鏡心投資合夥企業(有限合夥)) | | |
| Shanghai Hengyu Investment Management Consulting | 0.870% | 0.574% |
| Centre (Limited Partnership) | | |
| (上海珩予投資管理諮詢中心(有限合夥)) | | |
| Shanghai Healthcare Capital | - | 12.936% |
| JIC Investment Co., Ltd. | - | 5.272% |
| (建投投資有限責任公司) | | |
| 3nod Health Management Co., Ltd. | - | 4.946% |
| (三諾健康管理有限公司) | | |
| Jiaxing Changying Equity Investment Partnership | - | 3.314% |
| (Limited Partnership) | | |
| (嘉興常盈股權投資合夥企業(有限合夥)) | | |
| Shanghai Lianyun Enterprise Management Centre | - | 3.299% |
| (Limited Partnership) | | |
| (上海聯耘企業管理中心(有限合夥)) | | |
| Gongqingcheng Chenxi No.7 Equity Investment | - | 3.299% |
| Partnership (Limited Partnership) | | |
| (共青城晨熹七號股權投資合夥企業(有限合夥)) | | |
| Huadong Industry | - | 0.989% |
| Total | 100% | 100% |

Shanghai Healthcare Capital

Shanghai Healthcare Capital is a limited partnership, established under the PRC laws and is mainly engaged in equity investment, equity investment management, etc. The single largest shareholder of Shanghai Biomedical Industrial Fund is Shanghai Lubuka Corporation Management and Advisory Partnership (Limited Partnership) (上海鷺布卡企業管理咨詢合夥企業(有限合夥)), an Independent Third Party of the Company, holding 25.2% equity interest in Shanghai Biomedical Industrial Fund; Shanghai Shangshi Capital Management Co., Ltd. (上海上實資本管理有限公司), the Company, Shanghai Lingang Guanwei Investment Development Co., Ltd. (上海臨港管偉投資發展有限公司) and Shanghai Changning State-owned Assets Management Investment Co., Ltd. (上海長寧國有資產經營投資有限公司) holds 25.0%, 24.8%, 15.0% and 10.0% equity interest in Shanghai Biomedical Industrial Fund, respectively.

By Order of the Board Shanghai Pharmaceuticals Holding Co., Ltd.* ZHOU Jun

Chairman

Shanghai, the PRC, 24 February 2021

As of the date of this announcement, the executive Directors of the Company are Mr. CHO Man, Mr. LI Yongzhong and Mr. SHEN Bo; the non-executive Directors are Mr. ZHOU Jun, Mr. GE Dawei and Ms. LI An; and the independent non-executive Directors are Mr. CAI Jiangnan, Mr. HONG Liang, Mr. GU Zhaoyang and Mr. Manson FOK.

* For identification purpose only